

Tyler J Wildes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1587583/publications.pdf>

Version: 2024-02-01

30
papers

226
citations

1307594

7
h-index

1372567

10
g-index

30
all docs

30
docs citations

30
times ranked

393
citing authors

#	ARTICLE	IF	CITATIONS
1	Dendritic Cell-Activating Magnetic Nanoparticles Enable Early Prediction of Antitumor Response with Magnetic Resonance Imaging. <i>ACS Nano</i> , 2019, 13, 13884-13898.	14.6	66
2	Cross-talk between T Cells and Hematopoietic Stem Cells during Adoptive Cellular Therapy for Malignant Glioma. <i>Clinical Cancer Research</i> , 2018, 24, 3955-3966.	7.0	34
3	Lin ⁺ CCR2 ⁺ hematopoietic stem and progenitor cells overcome resistance to PD-1 blockade. <i>Nature Communications</i> , 2018, 9, 4313.	12.8	32
4	Immune Escape After Adoptive T-cell Therapy for Malignant Gliomas. <i>Clinical Cancer Research</i> , 2020, 26, 5689-5700.	7.0	26
5	RNA-Modified T Cells Mediate Effective Delivery of Immunomodulatory Cytokines to Brain Tumors. <i>Molecular Therapy</i> , 2019, 27, 837-849.	8.2	21
6	Massive clonal expansion of medulloblastoma-specific T cells during adoptive cellular therapy. <i>Science Advances</i> , 2019, 5, eaav9879.	10.3	17
7	Concise Review: Modulating Cancer Immunity with Hematopoietic Stem and Progenitor Cells. <i>Stem Cells</i> , 2019, 37, 166-175.	3.2	17
8	Myelopoiesis during Solid Cancers and Strategies for Immunotherapy. <i>Cells</i> , 2021, 10, 968.	4.1	7
9	Effect of atorvastatin on humoral immune response to 23-valent pneumococcal polysaccharide vaccination in healthy volunteers: The StatVax randomized clinical trial. <i>Vaccine</i> , 2019, 37, 1313-1324.	3.8	5
10	mRNA-nanoparticles to enhance and track dendritic cell migration.. <i>Journal of Clinical Oncology</i> , 2018, 36, 72-72.	1.6	1
11	IMPS-07 T CELL RECEPTOR VARIABLE β CHAIN (TCR $V\beta$) USAGE TO PREDICT AND GENERATE TUMOR SPECIFIC T LYMPHOCYTES AGAINST INVASIVE GLIOMAS. <i>Neuro-Oncology</i> , 2015, 17, v114.3-v114.	1.2	0
12	IM-15 * ANTI-TUMOR EFFICACY OF ADOPTIVE CELLULAR THERAPY IS SIGNIFICANTLY INCREASED BY HEMATOPOIETIC STEM CELLS. <i>Neuro-Oncology</i> , 2015, 17, iii18-iii18.	1.2	0
13	IMST-47. IDENTIFICATION AND EXPANSION OF GLIOMA-SPECIFIC T CELLS USING TCR $V\beta$ EXPRESSION. <i>Neuro-Oncology</i> , 2016, 18, vi97-vi97.	1.2	0
14	IMMU-65. Lin-CCR2+ HEMATOPOIETIC STEM CELLS OVERCOME RESISTANCE TO PD-1 BLOCKADE. <i>Neuro-Oncology</i> , 2017, 19, vi127-vi127.	1.2	0
15	IMMU-22. ADOPTIVE CELL THERAPY AGAINST DIPG USING DEVELOPMENTALLY REGULATED ANTIGENS. <i>Neuro-Oncology</i> , 2017, 19, iv32-iv32.	1.2	0
16	TMIC-12. REPROGRAMMING THE BRAIN TUMOR MICROENVIRONMENT WITH HEMATOPOIETIC STEM AND PROGENITOR CELLS. <i>Neuro-Oncology</i> , 2017, 19, vi245-vi245.	1.2	0
17	IMMU-30. TCR $V\beta$ CLONAL EXPANSION PREDICTS RESPONSE TO ADOPTIVE IMMUNOTHERAPY AGAINST MEDULLOBLASTOMA. <i>Neuro-Oncology</i> , 2017, 19, vi119-vi119.	1.2	0
18	TMIC-29. REPROGRAMMING BONE MARROW OF TUMOR-BEARING HOSTS FOR GLIOMA IMMUNOTHERAPY. <i>Neuro-Oncology</i> , 2018, 20, vi262-vi262.	1.2	0

#	ARTICLE	IF	CITATIONS
19	IMMU-24. THE IMPACT OF BRAIN TUMORS ON HEMATOPOIETIC STEM CELL-DERIVED T CELLS. <i>Neuro-Oncology</i> , 2018, 20, vi126-vi126.	1.2	0
20	TMIC-12. TUMOR-HOMING RNA-NANOPARTICLES REPROGRAM IMMUNE CELLS IN THE BRAIN TUMOR MICROENVIRONMENT. <i>Neuro-Oncology</i> , 2018, 20, vi258-vi258.	1.2	0
21	EXTH-36. BIFUNCTIONAL RNA NANOPARTICLES INDUCE ANTITUMOR IMMUNE RESPONSES AND ALLOW MRI-BASED DETECTION OF DENDRITIC CELL MIGRATION AS A BIOMARKER OF ANTITUMOR IMMUNE RESPONSE. <i>Neuro-Oncology</i> , 2018, 20, vi92-vi93.	1.2	0
22	IMMU-32. RETARGETING IMMUNOEDITED GLIOMA ESCAPE VARIANTS WITH ADOPTIVE CELLULAR THERAPY. <i>Neuro-Oncology</i> , 2018, 20, vi128-vi128.	1.2	0
23	IMMU-17. HEMATOPOIETIC STEM CELL-DERIVED DENDRITIC CELLS REPROGRAM THE BRAIN TUMOR MICROENVIRONMENT. <i>Neuro-Oncology</i> , 2018, 20, i102-i102.	1.2	0
24	IMMU-20. HEMATOPOIETIC STEM CELLS POTENTIATE EFFICACY OF ADOPTIVE CELL THERAPY AGAINST BRAIN STEM GLIOMA. <i>Neuro-Oncology</i> , 2018, 20, i102-i103.	1.2	0
25	MBRS-63. CCR2+ HEMATOPOIETIC STEM CELLS OVERCOME TREATMENT RESISTANCE TO PD-1 IN MEDULLOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, i141-i142.	1.2	0
26	Identification of Tumor Specific Lymphocytes Cells in a Murine Glioma Model. <i>Neurosurgery</i> , 2019, 66, 310-638.	1.1	0
27	Abstract 4075: Overcoming glioma immunoediting and MHC class I loss during adoptive cellular therapy. , 2019, , .		0
28	Abstract 1194: Adoptive cellular therapy overcomes tumor-induced dysregulation of myelopoiesis. , 2019, , .		0
29	Abstract 1194: Adoptive cellular therapy overcomes tumor-induced dysregulation of myelopoiesis. , 2019, , .		0
30	Abstract 4075: Overcoming glioma immunoediting and MHC class I loss during adoptive cellular therapy. , 2019, , .		0